Ten months into the pandemic, the research community is making rapid progress toward developing a safe and effective COVID-19 vaccine, with several vaccines in Phase 3 trials in the US alone. Despite this remarkable speed, concerned citizens and members of the medical and public health communities naturally have questions: What does it mean about overall safety and effectiveness that some projects have been paused to ensure the safety and health of vaccine trial participants? Who has been included in the trial process, and how representative are they of our society? When the first vaccines are found to be safe and effective, how effective can we expect them to be, based on current indications?
Join Duke Science & Society and their guests, who are overseeing COVID-19 vaccine trials for Moderna and Pfizer, in a discussion of how the COVID-19 vaccine trials are progressing in the U.S, what current indications are about their safety and efficacy, and when we can expect initial approvals for early or limited use.
Moderator
Nita Farahany, JD, PhD, Director, Duke Initiative For Science & Society
Duke University
Panelists
Cindy Gay, MD, MPH, Principal Investigator, Moderna SARS-COV-2 vaccine trial
University of North Carolina at Chapel Hill
Emmanuel Walter, MD, Principal Investigator, Pfizer SARS-COV-2 vaccine trial
Duke University